Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
Date:4/28/2008

NEW YORK, April 28 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc. (OTC Bulletin Board: ADXS). The full 60-page report can be found at http://www.crystalra.com.

Advaxis, Inc. ("Advaxis" or "the Company") uses live, genetically modified Listeria monocytogenes ("Listeria") to safely create vaccines that stimulate multiple immune responses against cancer as well as infectious and immune disorders. Through patented techniques, the Company engineers the Listeria bacteria to secrete a specific antigen. The recipients' immune system recognizes and processes that antigen in order to provoke an immune attack against the cancer. Advaxis' Listeria platform technology is licensed from the University of Pennsylvania, where it has been developed over the past 15 years by Dr. Yvonne Paterson, the scientific founder of the Company and current chair of its Scientific Advisory Board.

At present, Advaxis is engineering Listeria to fight cervical intraepithelial neoplasia ("CIN") and cervical, head and neck, prostate, breast, and other cancers. The cancer vaccine market is forecast to reach over $8 billion by 2012, up from $481 million in 2007. In preclinical studies, Listeria-based cancer vaccines have a 100% therapeutic response rate and consistently provoke tumor regression, completely eliminating tumors in over 50% of mice. Moreover, animals dosed with these vaccines show a long-term immunity against cancer, with new tumor cells unable to grow. This suggests that the technology can not only treat existing tumors but may also prevent cancer recurrence.

In 2007, Advaxis completed its first human clinical trial of the Listeria platform using Lovaxin C, a vaccine for human papillomavirus (HPV)-derived cervical cancer. In the Phase I trial, the vaccine has been shown to be safely administered to humans and well tolerated. To Advaxis' knowledge, it is the first entity to safely administer live Listeria as an antigen carrier and immune system stimulant in humans. A Phase II clinical trial is planned for patients with CIN I/II in 2008.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and Delray Beach. Crystal Research Associates has been compensated by the Company in cash of forty thousand U.S. dollars and four hundred thousand four-year Options/Warrants to purchase Advaxis' stock for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with SEC.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
2. Alara Receives FDA Clearance to Market CRystalView T-Series CR system
3. A New Year, A New Opportunity: Metropolitan Community Church Leaders Urge Faith Leaders to Address HIV and Crystal Meth Use Among LGBT Youth
4. Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages
5. Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women
6. Measurement technique probes surface structure of gold nanocrystals
7. Stanford researchers find culprit in aging muscles that heal poorly
8. Children of depressed moms do better when dad is involved, SLU researcher finds
9. UCLA researchers identify markers that may predict diabetes in still-healthy people
10. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
11. New research shows how chronic stress worsens neurodegenerative disease course
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... Cypress in Sun City is the place to be on March 3rd to learn about ... will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will ... offers. In addition, prizes will be given away and light refreshments will be served. ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Voices of Recovery, the leading national organization representing the growing community of recovering ... public office to include Family Recovery in policies addressing addiction. , Although ...
(Date:2/13/2016)... ... February 13, 2016 , ... With FCPX Overlay Embers from ... all within Final Cut Pro X. Each user can select from up to 40 ... of view, blur, focus offset, hue, saturation, value, contrast, glow, and more all within ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... Nurses Society (INS) states that vein visualization technology should be used to ensure ... facilities around the world, the INS Standards mandate the use of vein visualization ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Calif. , Feb. 12, 2016  SI-BONE, Inc., a medical ... ® ("iFuse"), a minimally invasive surgical (MIS) device indicated for ... National Government Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering ... , Maine , Massachusetts ... , New York , Rhode Island ...
(Date:2/12/2016)... , Feb. 12, 2016  Sequent Medical, Inc. ... a study to evaluate the safety and effectiveness of ... treatment of ruptured intracranial aneurysms.  Prof Laurent Spelle ... in Paris, France and Principal ... France and Germany.  Although ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company (NYSE: ... decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not ... UK, France , Italy ... dilute the product only with dextrose solution.  ... the UK Court of Appeal held that Lilly,s patent would ...
Breaking Medicine Technology: